In the Boardroom - Forest Laboratories, Anti-virals

Filter

Popular Filters

1 to 25 of 568 results

Jacques Servier, founder and president of Lab Servier, dies aged 92

17-04-2014

French independent drugmaker Laboratories Servier announced that its founder and president, Jacques Servier,…

BoardroomManagementPharmaceuticalServier

Astellas US promotes Jeffrey Bloss to SVP of medical affairs for the Americas

Astellas US promotes Jeffrey Bloss to SVP of medical affairs for the Americas

16-04-2014

The US subsidiary of Japanese drug major Astellas Pharma announced that Jeffrey Bloss has been promoted…

Astellas PharmaBoardroomManagementPharmaceuticalUSA

AbbVie achieves response rate of 96% in Phase III trials of hepatitis C treatment

AbbVie achieves response rate of 96% in Phase III trials of hepatitis C treatment

14-04-2014

US drugmaker AbbVie has revealed promising new results from its hepatitis C development program at the…

AbbVieAnti-viralsPharmaceuticalResearchUSA

Impressive data for once-daily sofosbuvir and ledipasvir treatment of HCV genotype 1

12-04-2014

Strong results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational…

Anti-viralsBiotechnologyGilead SciencesledipasvirResearchsofosbuvirSovaldi

Bristol-Myers’ all-oral daclatasvir and asunaprevir combo shines in Ph III

Bristol-Myers’ all-oral daclatasvir and asunaprevir combo shines in Ph III

10-04-2014

US pharma major Bristol-Myers Squibb has presented new Phase III trial data of its combination therapy…

Anti-viralsasunaprevirBristol-Myers SquibbdaclatasvirPharmaceuticalResearch

Promising results for Merck & Co’s hepatitis C drug combo

Promising results for Merck & Co’s hepatitis C drug combo

10-04-2014

US pharma giant Merck & Co has announced additional data from the ongoing C-WORTHy study, a multi-arm…

Anti-viralsMerck & CoMK-5172PharmaceuticalResearch

Sovaldi effective for retreatment of chronic hepatitis C in patients not cured with prior antiviral therapy

Sovaldi effective for retreatment of chronic hepatitis C in patients not cured with prior antiviral therapy

10-04-2014

US antivirals major Gilead Sciences today announced positive findings from an open-label clinical trial…

Anti-viralsBiotechnologyGilead SciencesResearchSovaldi

Forest and Almirall get FDA feedback on fixed dose combo of aclidinium and formoterol

Forest and Almirall get FDA feedback on fixed dose combo of aclidinium and formoterol

09-04-2014

US drugmaker Forest Laboratories and partner Almirall, Spain’s largest pharma company, say they have…

aclidiniumAlmirallForest LaboratoriesformoterolNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryUSA

Express Scripts forecasts unsustainable increases in specialty drug spend in USA

Express Scripts forecasts unsustainable increases in specialty drug spend in USA

09-04-2014

Expensive treatments for broad patient populations are driving unprecedented growth in US spending on…

Anti-Arthritics/RheumaticsAnti-viralsMarkets & MarketingNorth AmericaOncologyPharmaceuticalPricingUSA

FDA priority review for Gilead’s ledipasvir/sofosbuvir fixed-dose combo for hepatitis C

FDA priority review for Gilead’s ledipasvir/sofosbuvir fixed-dose combo for hepatitis C

08-04-2014

US anti-virals major Gilead Sciences says that the US Food and Drug Administration has granted priority…

Anti-viralsBiotechnologyGilead SciencesledipasvirNorth AmericaRegulationsofosbuvirUSA

Bristol-Myers Squibb files for US approval of daclatasvir and asunaprevir for hepatitis C

Bristol-Myers Squibb files for US approval of daclatasvir and asunaprevir for hepatitis C

07-04-2014

US pharma major Bristol-Myers Squibb has submitted New Drug Applications with the US Food and Drug Administration…

Anti-viralsasunaprevirBristol-Myers SquibbdaclatasvirNorth AmericaPharmaceuticalRegulationUSA

Germany’s IQWiG views Xofigo, Kadcyla and Eviplera

03-04-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products, the…

Anti-viralsBayerEvipleraGermanyGilead SciencesKadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheXofigo

Global Fund taps pharmaceutical expertise in China

02-04-2014

The Global Fund is deepening its partnership with China by tapping the expertise of Chinese pharmaceutical…

Anti-viralsAntibiotics and Infectious diseasesChinaGlobalMarkets & MarketingPharmaceuticalProductionRegulation

New Haven Pharmaceuticals appoints Larry Dillaha as Executive Vice President Operations

New Haven Pharmaceuticals appoints Larry Dillaha as Executive Vice President Operations

02-04-2014

New Haven Pharmaceuticals, a privately held specialty pharmaceuticals company, today announced the appointment…

BoardroomNew Haven PharmaceuticalsPharmaceuticalUSA

ViiV Healthcare grants licence to Medicines Patent Pool to improve access to Tivicay

ViiV Healthcare grants licence to Medicines Patent Pool to improve access to Tivicay

02-04-2014

Viiv Healthcare, the HIV/AIDS joint venture of UK pharma giant GlaxoSmithKline, US drugmaker Pfizer and…

Anti-viralsGlobalPharmaceuticalPricingTivicayViiV Healthcare

Paul Sekhri joins Sanofi as Senior Vice President

Paul Sekhri joins Sanofi as Senior Vice President

01-04-2014

Paul Sekhri has joined French drug major Sanofi as Senior Vice President, Integrated Care effective…

BiotechnologyBoardroomPharmaceuticalSanofiUSA

Janssen files new NDA for combination HIV drug containing darunavir

Janssen files new NDA for combination HIV drug containing darunavir

01-04-2014

US health care giant Johnson & Johnson’s Europe-based subsidiary Janssen has submitted a New Drug Application…

Anti-viralsDarunavirJanssenPharmaceuticalPrezistaRegulationUSA

Inovio Pharmaceuticals appoints EJ Brandreth as vice president of quality

Inovio Pharmaceuticals appoints EJ Brandreth as vice president of quality

01-04-2014

USA-based Inovio Pharmaceuticals (NYSE MKT: INO) has announced the appointment of EJ Brandreth as Vice…

BoardroomInovio PharmaceuticalsPharmaceuticalUSA

Par Pharmaceutical appoints Terrance Coughlin as chief operating officer

Par Pharmaceutical appoints Terrance Coughlin as chief operating officer

01-04-2014

Par Pharmaceutical Companies (NYSE: PRX) has announced the appointment of Terrance Coughlin as chief…

BoardroomPar PharmaceuticalPar PharmaceuticalsPharmaceuticalUSA

Sanofi appoints Dr Anne Beal as chief patient officer

Sanofi appoints Dr Anne Beal as chief patient officer

31-03-2014

French drug major Sanofi has announced the appointment of Anne Beal to the newly created position of…

BiotechnologyBoardroomFrancePharmaceuticalSanofiUSA

1 to 25 of 568 results

Back to top